PMID- 34422633
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto's 
      Thyroiditis.
PG  - 680873
LID - 10.3389/fonc.2021.680873 [doi]
LID - 680873
AB  - BACKGROUND: Papillary thyroid carcinoma (PTC) concurrent with Hashimoto's 
      thyroiditis (HT) was associated with a better clinical prognosis. This study 
      aimed to investigate a potential mRNA gene that affects the development of PTC, 
      which helps PTC concurrent with HT patients have a better prognosis. 
      MATERIAL/METHODS: PTC data were obtained from The Cancer Genome Atlas (TCGA) 
      database. And the validation data of tissue specimens were collected from 
      Guangzhou First People's Hospital. The thyroid tissue sections were hybridized 
      with deleted in malignant brain tumor 1 (DMBT1) probes by situ hybridization. 
      Survival rates were analyzed using Kaplan-Meier curves, and the log-rank test was 
      used to compare group survival rates. Prognosis clinicopathological factors were 
      analyzed by Cox regression. Gene Ontology (GO) and Kyoto Gene and Genomic 
      Encyclopedia (KEGG) pathway enrichment analyses were performed using 
      single-sample gene set enrichment analysis (ssGSEA). Finally, the correlation of 
      deletion in DMBT1 expression with overall immune status, tumor purity, and human 
      leukocyte antigen (HLA) gene expression profile was analyzed. RESULTS: HT was 
      significantly associated with sex, tumor foci, extrathyroidal extension (ETE), 
      residual tumor, and tumor stage (T stage). Moreover, PTC concurrent with HT had a 
      lower risk of recurrence versus non-HT groups. A total of 136 differentially 
      expressed mRNAs (DEMs) were identified between HT and non-HT groups. Among them, 
      the expression level of DMBT1 in HT groups was statistically higher than that in 
      non-HT groups. A significant association with ETE and recurrence was revealed in 
      the high expression and the low expression of DMBT1. Furthermore, DMBT1 was an 
      independent predictor of survival. The overall immune activity of high expression 
      of DMBT1 was higher than that of the low-expression group. CONCLUSIONS: The PTC 
      patients with HT had better behavior features and prognosis than those with 
      simple PTC. DMBT1 in PTC-HT patients was a potential possible factor that 
      inhibits tumors. High expression of DMBT1 may improve PTC prognosis by 
      immune-related pathways.
CI  - Copyright (c) 2021 Gan, Li, Li, Mo, Feng, Shen, Cai, Lai and Xu.
FAU - Gan, Xiao-Xiong
AU  - Gan XX
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Li, Ya-Yi
AU  - Li YY
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Li, Si-Jin
AU  - Li SJ
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Mo, Shi-Sen
AU  - Mo SS
AD  - General Surgery, Guangzhou First People's Hospital, School of Medicine, South 
      China University of Technology, Guangzhou, China.
FAU - Feng, Jian-Hua
AU  - Feng JH
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Shen, Fei
AU  - Shen F
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Cai, Wen-Song
AU  - Cai WS
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Lai, Ye-Qian
AU  - Lai YQ
AD  - Department of Thyroid Surgery, Meizhou People's Hospital, Meizhou City, China.
FAU - Xu, Bo
AU  - Xu B
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210804
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8372325
OTO - NOTNLM
OT  - Hashimoto's thyroiditis
OT  - immune gene
OT  - papillary thyroid carcinoma
OT  - prognosis
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
PMCR- 2021/01/01
CRDT- 2021/08/23 06:35
PHST- 2021/03/15 00:00 [received]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/08/23 06:35 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.680873 [doi]
PST - epublish
SO  - Front Oncol. 2021 Aug 4;11:680873. doi: 10.3389/fonc.2021.680873. eCollection 
      2021.